FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:1393-1395 September 25, 2008 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Hacke, W. PubMed Citation

Stroke, the most common cause of disability in the world among adults, remains the only neurologic disorder for which physicians are potentially able to completely reverse disabling deficits.¹ Thrombolytic therapy, which can restore neurologic functions if given early enough, not only has stood the test of time, shown benefit in serial community registries on multiple continents, and received approval by every major regulatory authority in the world, but also has now — once again — been shown in a randomized, blinded, placebo-controlled trial to be efficacious. The results of the European Cooperative Acute Stroke Study III (ECASS III)² (ClinicalTrials.gov number, . . . [Full Text of this Article]

Source Information

From the Department of Neurology, Veterans Affairs Medical Center, San Diego, and the Department of Neurosciences, University of California, San Diego, School of Medicine — both in San Diego, CA.

This article has been cited by other articles:

• (2008). Thrombolysis for Stroke Within 4.5 Hours Is Safe and Effective. JWatch Emergency Med. 2008: 1-1 [Full Text]